Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


EASL 2020 Virtual Conference: Rapid Audio Recap

August 27-29, 2020; Virtual
Hear insights from hepatology expert, Stefan Zeuzem, MD, on some of the most important new viral hepatitis data reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver. The studies highlighted in this podcast focus on HCV elimination and the treatment of HCV, HBV, and HDV infection.
Stefan Zeuzem, MD
Released: September 14, 2020

In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:

  • Update on global progress toward HCV elimination goals
  • SToP-C: HCV treatment-as-prevention in Australian prisons
  • SHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOX
  • Trio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failure
  • Stop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infection
  • High-dose bulevirtide for chronic HBV/HDV coinfection
  • Summary of select agents under early-phase investigation for HBV treatment

Content based on a CME program supported by an independent educational grant from Gilead Sciences.

Link to full program: https://www.clinicaloptions.com/hepatitis/conference-coverage/easl-2020/highlights


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Educational grant provided by
Gilead Sciences

Related Content

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

CCO commentary from Anna Christina L. dela Cruz, MD, on the use of quantitative HBsAg and elastography in the management of hepatitis B

Anna Christina L. dela Cruz, MD Released: August 18, 2020

Download free expert-authored slides reviewing HBV management recommendations for specific patient populations and learn how expert faculty approach complex cases

person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD Released: July 21, 2020

Watch this interactive presentation from CCO to learn how expert faculty weigh factors to determine the optimal management strategy for complex patients with HBV infection

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Program Director
person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: July 20, 2020 Expired: July 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?